1
|
Shafer P, Leung WK, Woods ML, Rodriguez-Plata C, Ali A, Nalawade S, Kelley LM, Joubert J, Manliguez A, Vasileiou S, Fuqua SA, Lulla P, Rooney C, Leen A, Hoyos V. Abstract P6-10-11: Engineered neoantigen-specific T cell receptors to treat metastatic breast cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p6-10-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
T cell receptor engineered T cell (TCR T) therapy has emerged as a promising therapeutic modality for solid cancer following recent trials demonstrating the safety and efficacy of TCR T therapies against some types of metastatic solid cancers. However, the broader application of TCR T towards many solid tumors, including metastatic breast cancer (MBC), has been limited by several factors, chiefly among them the current scarcity of tumor selective target antigens. Neoantigens, which are expressed exclusively in cancer cells, are currently underrepresented in TCR T development, being targeted in only about 7% of trials conducted to date, and thus represent a relatively untapped source of potentially safe and effective novel targets. Driver mutations in AKT1, ESR1, PIK3CA, and TP53 are common in patients with MBC, and could serve as ideal neoantigen targets for TCR T therapies. We hypothesized that we could generate MBC driver mutation-specific T cells from which we could isolate and clone neoantigen-specific TCRs to generate TCR T products for MBC. We identified 13 driver missense mutations that are among the most frequent in patients with MBC, which included AKT1 (E17K), ESR1 (K303R, Y537S, D538G), PIK3CA (E542K, E545K, H1047L, H1047R), and TP53 (R175H, R248Q, R248W, R273C, R273H), then designed peptide libraries consisting of 15-mer overlapping peptides that contain these mutations. To determine if these neopeptides could elicit T cell responses, we isolated T cells from 15 healthy donors and 11 MBC patients who expressed at least one of the targeted mutations and performed successive stimulations with neopeptide pulsed dendritic cells, then screened the resulting T cell lines for neoantigen specificity using an IFN-γ ELISpot assay. We observed neopeptide T cell responses in 8/16 lines generated from healthy donors and 7/11 lines generated from MBC patients, which were collectively directed against 11/13 of the targeted driver mutations. To isolate neoantigen-specific TCRs from one of these lines, we performed IFN-γ capture, limiting dilution, and 5’ RACE, and isolated an HLA-B*35 restricted TP53 R248W-specifc TCR. Gene transfer of this TCR conferred edited T cells with potent activity towards the TP53 R248W and not the TP53 WT peptide as assessed by ELISpot (1036 vs 46 SFU/1 × 105 cells, respectively) and chromium release cytoxicity assay targeting peptide pulsed autologous PHA blasts (37.5% vs 0% lysis at E:T 40:1, respectively). To increase the throughput of TCR discovery, we next used a single cell RNA sequencing based TCR discovery approach whereby we stimulated T cells from one of the generated lines with ESR1 WT or neopeptide and identified responsive T cell clones through upregulation of IFN-γ and/or TNF-α. This strategy has so far enabled us to identify and validate two ESR1 mutant-specific TCRs. This includes an HLA-C*01 restricted TCR that confers edited T cells with dual activity towards both ESR1 Y537S and D538G, but not WT peptide as determined by both ELISpot (2094, 3194, and 79 SFU, respectively) and chromium release cytotoxicity (31.3%, 77.8%, and 9.1% lysis, respectively), as well as an HLA-B*40 restricted TCR that confers high ESR1 Y537S specificity (5039 vs 138 SFU in response to ESR1 Y537S vs WT peptide, respectively). In summary, we have demonstrated responses of T cells derived from both healthy donors and MBC patients towards neopeptides derived from common MBC driver mutations. We have so far isolated neoantigen specific TCRs from two of the neoantigen-specific T cells lines, including TCRs specific towards TP53 R248W, ESR1 Y537S, dual ESR1 Y537S+D538G that are restricted to three different HLA alleles, and have successfully used these TCRs to generate TCR T products with high neoantigen activity. These results encourage further efforts to identify TCRs recognizing these MBC driver mutations, with our ultimate aim to translate neoantigen-targeted TCR T therapies to clinical trials of MBC.
Citation Format: Paul Shafer, Wingchi K. Leung, Mae L. Woods, Carlos Rodriguez-Plata, Arushana Ali, Saisha Nalawade, Lauren M. Kelley, Jarrett Joubert, Anthony Manliguez, Spyridoula Vasileiou, Suzanne A. Fuqua, Premal Lulla, Cliona Rooney, Ann Leen, Valentina Hoyos. Engineered neoantigen-specific T cell receptors to treat metastatic breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-10-11.
Collapse
Affiliation(s)
| | | | - Mae L. Woods
- 3Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Medrano MT, Nalawade S, Huizar CC, Yuhara A, Forsthuber TG. Collaboration between Osteopontin and Macrophage Migration Inhibitory Factor in Autoimmune Myocarditis. The Journal of Immunology 2022. [DOI: 10.4049/jimmunol.208.supp.108.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine elevated in multiple conditions. MIF is also elevated in autoimmune myocarditis (AM), a condition in which the immune system aberrantly attacks the heart muscle. AM can be induced by antigenic mimicry, autoimmune stimulation, genetic defects, issues with regulatory T cells, dysregulation of immune effector cells. AM also has the possibility to progress to the fatal disease dilated cardiomyopathy (DCM) through chronic inflammation, the deposition and crosslinking of collagen, proliferation by fibroblasts, and differentiation into myofibroblasts. Our lab has previously shown that MIF and OPN synergize to enhance the progression of disease to DCM, by affecting cardiac fibrosis and the deposition of collagen. Glucocorticoids (GCs) are given to suppress the inflammation caused by immune reactions and therefore are prescribed as treatment for autoimmune myocarditis. However, GCs are unable prevent the progression of AM to DCM. Our lab investigated the role of GCs for promoting the actions of MIF by enhancing the OPN-dependent deposition of collagen in the myocardium by gene expression of extracellular matrix proteins affected by AM through qPCR and their protein concentration by ELISA. Establishing a pathway for collagen deposition in AM will allow for the development of more effective treatment and prevention of the progression to DCM.
Collapse
Affiliation(s)
- Megan T Medrano
- 1Department of Molecular Microbiology and Immunology, University of Texas San Antonio
| | - Saisha Nalawade
- 2Center for Cell and Gene Therapy, Baylor College of Medicine
| | - Carol Chase Huizar
- 1Department of Molecular Microbiology and Immunology, University of Texas San Antonio
| | - Alec Yuhara
- 1Department of Molecular Microbiology and Immunology, University of Texas San Antonio
| | - Thomas G Forsthuber
- 1Department of Molecular Microbiology and Immunology, University of Texas San Antonio
| |
Collapse
|
3
|
Raphael I, Gomez-Rivera F, Raphael RA, Robinson RR, Nalawade S, Forsthuber TG. TNFR2 limits proinflammatory astrocyte functions during EAE induced by pathogenic DR2b-restricted T cells. JCI Insight 2019; 4:132527. [PMID: 31852844 DOI: 10.1172/jci.insight.132527] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Accepted: 11/13/2019] [Indexed: 12/16/2022] Open
Abstract
Multiple sclerosis (MS) is an autoimmune neuroinflammatory disease where the underlying mechanisms driving disease progression have remained unresolved. HLA-DR2b (DRB1*15:01) is the most common genetic risk factor for MS. Additionally, TNF and its receptors TNFR1 and TNFR2 play key roles in MS and its preclinical animal model, experimental autoimmune encephalomyelitis (EAE). TNFR2 is believed to ameliorate CNS pathology by promoting remyelination and Treg function. Here, we show that transgenic mice expressing the human MHC class II (MHC-II) allele HLA-DR2b and lacking mouse MHC-II and TNFR2 molecules, herein called DR2bΔR2, developed progressive EAE, while disease was not progressive in DR2b littermates. Mechanistically, expression of the HLA-DR2b favored Th17 cell development, whereas T cell-independent TNFR2 expression was critical for restraining of an astrogliosis-induced proinflammatory milieu and Th17 cell responses, while promoting remyelination. Our data suggest the TNFR2 signaling pathway as a potentially novel mechanism for curtailing astrogliosis and promoting remyelination, thus providing new insights into mechanisms limiting progressive MS.
Collapse
Affiliation(s)
- Itay Raphael
- Department of Neurological Surgery, University of Pittsburgh, UPMC Children's Hospital, Pittsburgh, Pennsylvania, USA.,Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA
| | - Francisco Gomez-Rivera
- Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA.,Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
| | - Rebecca A Raphael
- Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA.,Department of Pharmacology and Chemical Biology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
| | - Rachel R Robinson
- Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA
| | - Saisha Nalawade
- Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA.,Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA
| | - Thomas G Forsthuber
- Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA
| |
Collapse
|
4
|
Bloom J, Metz C, Nalawade S, Casabar J, Cheng KF, He M, Sherry B, Coleman T, Forsthuber T, Al-Abed Y. Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. J Biol Chem 2016; 291:26502-26514. [PMID: 27793992 DOI: 10.1074/jbc.m116.743328] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2016] [Revised: 09/27/2016] [Indexed: 12/11/2022] Open
Abstract
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that has been implicated in a broad range of inflammatory and oncologic diseases. MIF is unique among cytokines in terms of its release profile and inflammatory role, notably as an endogenous counter-regulator of the anti-inflammatory effects of glucocorticoids. In addition, it exhibits a catalytic tautomerase activity amenable to the design of high affinity small molecule inhibitors. Although several classes of these compounds have been identified, biologic characterization of these molecules remains a topic of active investigation. In this study, we used in vitro LPS-driven assays to characterize representative molecules from several classes of MIF inhibitors. We determined that MIF inhibitors exhibit distinct profiles of anti-inflammatory activity, especially with regard to TNFα. We further investigated a molecule with relatively low anti-inflammatory activity, compound T-614 (also known as the anti-rheumatic drug iguratimod), and found that, in addition to exhibiting selective MIF inhibition in vitro and in vivo, iguratimod also has additive effects with glucocorticoids. Furthermore, we found that iguratimod synergizes with glucocorticoids in attenuating experimental autoimmune encephalitis, a model of multiple sclerosis. Our work identifies iguratimod as a valuable new candidate for drug repurposing to MIF-relevant diseases, including multiple sclerosis.
Collapse
Affiliation(s)
- Joshua Bloom
- From the Hofstra-Northwell School of Medicine, Hempstead, New York 11549, .,the Centers for Molecular Innovation
| | - Christine Metz
- From the Hofstra-Northwell School of Medicine, Hempstead, New York 11549.,Biomedical Sciences, and
| | - Saisha Nalawade
- the Department of Biology, University of Texas at San Antonio, San Antonio, Texas 78249
| | - Julian Casabar
- the Department of Biology, University of Texas at San Antonio, San Antonio, Texas 78249
| | | | | | - Barbara Sherry
- From the Hofstra-Northwell School of Medicine, Hempstead, New York 11549.,Immunology and Inflammation, and
| | - Thomas Coleman
- the Office of Technology Transfer, The Feinstein Institute for Medical Research, Manhasset, New York 11030, and
| | - Thomas Forsthuber
- the Department of Biology, University of Texas at San Antonio, San Antonio, Texas 78249
| | - Yousef Al-Abed
- From the Hofstra-Northwell School of Medicine, Hempstead, New York 11549, .,the Centers for Molecular Innovation
| |
Collapse
|
5
|
Affiliation(s)
- A Nagral
- Department of Medicine, Kasturba Hospital of Infectious Diseases, Mumbai, 400 011, India.
- Department of Gastroenterology, Jaslok Hospital, 15, Dr. Deshmukh Marg, Pedder Road, Mumbai, 400 026, India.
| | - A Jhaveri
- Department of Gastroenterology, Jaslok Hospital, 15, Dr. Deshmukh Marg, Pedder Road, Mumbai, 400 026, India
| | - S Nalawade
- Department of Medicine, Kasturba Hospital of Infectious Diseases, Mumbai, 400 011, India
| | - N Momaya
- Department of Ophthalmology, Bhatia Hospital, Tukaram Javaji Marg, Grant Road West, Tardeo, Mumbai, 400 007, India
| | - V Chakkarwar
- Department of Medicine, Kasturba Hospital of Infectious Diseases, Mumbai, 400 011, India
| | - P Malde
- Department of Medicine, Kasturba Hospital of Infectious Diseases, Mumbai, 400 011, India
| |
Collapse
|
6
|
Nalawade S, Jamison B, Casabar J, Maldonado D, Forsthuber T. MIF inhibition as novel treatment for autoimmune myocarditis and dilated cardiomyopathy (THER7P.956). The Journal of Immunology 2015. [DOI: 10.4049/jimmunol.194.supp.208.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Myocarditis is an inflammatory disease of the myocardium and a major cause of sudden death in young adults. It is characterized by the presence of immune infiltrates in the myocardium and often progresses to dilated cardiomyopathy (DCM). Despite the inflammatory nature of this autoimmune disease, immunosuppressive treatments with glucocorticoids (GCs) such as dexamethasone (Dex) have not been very effective in preventing myocarditis and progression to DCM. In addition, some patients develop resistance to GCs. We hypothesized that macrophage migration inhibitory factor (MIF) may play a role in resistance to GCs, as it is the only known pro-inflammatory cytokine to be induced by GCs. Importantly, MIF counter-regulates GC-mediated immunosuppression. Using the experimental autoimmune myocarditis (EAM) model, we observed that MIF-/- mice treated with Dex were highly resistant to disease and progression to DCM. In addition, we observe lower expression of CCL3 mRNA in MIF-/- mice treated with Dex compared with wild-type mice during the onset of EAM, which indicates that MIF promotes recruitment of inflammatory cells to the myocardium. Our results suggest that therapeutic inhibition of MIF may increase the efficacy of GC treatment. This study will allow us to better understand the mechanism by which MIF affects treatment of myocarditis by inhibiting the therapeutic effects of GCs.
Collapse
Affiliation(s)
- Saisha Nalawade
- 1Biology, University of Texas at San Antonio, San Antonio, TX
| | | | - Julian Casabar
- 1Biology, University of Texas at San Antonio, San Antonio, TX
| | | | | |
Collapse
|
7
|
Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 2014; 74:5-17. [PMID: 25458968 DOI: 10.1016/j.cyto.2014.09.011] [Citation(s) in RCA: 677] [Impact Index Per Article: 67.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2014] [Revised: 09/26/2014] [Accepted: 09/29/2014] [Indexed: 12/17/2022]
Abstract
CD4(+) T helper (Th) cells are critical for proper immune cell homeostasis and host defense, but are also major contributors to pathology of autoimmune and inflammatory diseases. Since the discovery of the Th1/Th2 dichotomy, many additional Th subsets were discovered, each with a unique cytokine profile, functional properties, and presumed role in autoimmune tissue pathology. This includes Th1, Th2, Th17, Th22, Th9, and Treg cells which are characterized by specific cytokine profiles. Cytokines produced by these Th subsets play a critical role in immune cell differentiation, effector subset commitment, and in directing the effector response. Cytokines are often categorized into proinflammatory and anti-inflammatory cytokines and linked to Th subsets expressing them. This article reviews the different Th subsets in terms of cytokine profiles, how these cytokines influence and shape the immune response, and their relative roles in promoting pathology in autoimmune and inflammatory diseases. Furthermore, we will discuss whether Th cell pathogenicity can be defined solely based on their cytokine profiles and whether rigid definition of a Th cell subset by its cytokine profile is helpful.
Collapse
Affiliation(s)
- Itay Raphael
- Department of Biology, University of Texas at San Antonio, TX 78249, United States
| | - Saisha Nalawade
- Department of Biology, University of Texas at San Antonio, TX 78249, United States
| | - Todd N Eagar
- Department of Pathology and Genomic Medicine, Houston Methodist Hospital, TX 77030, United States
| | - Thomas G Forsthuber
- Department of Biology, University of Texas at San Antonio, TX 78249, United States.
| |
Collapse
|
8
|
Hingmann R, Gutmann P, Nalawade S, Sommer MK, Thümen A, Yang X. Technologie-Entwicklung für die Verarbeitung, Aufbereitung und Formgebung von Thermoplasten. CHEM-ING-TECH 2012. [DOI: 10.1002/cite.201250086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|